Complement C3 activation is required for antiphospholipid antibody-induced fetal loss.
about
Tolerance of the fetus by the maternal immune system: role of inflammatory mediators at the feto-maternal interfaceSystemic lupus erythematosus: strategies to improve pregnancy outcomesAntiphospholipid antibodies and the placenta: a systematic review of their in vitro effects and modulation by treatmentComplement activation is critical for placental ischemia-induced hypertension in the rat.Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2.Uterine artery velocity waveforms as predictors of pregnancy outcome in patients with antiphospholipid syndrome: a review.Expression of immunomodulatory genes, their protein products and specific ligands/receptors during the window of implantation in the human endometrium.Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients.The systemic nature of the antiphospholipid syndrome.Complement factor H: using atomic resolution structure to illuminate disease mechanisms.36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature.Microangiopathic antiphospholipid antibody-associated syndrome in a pregnant lady.The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia.Serum Protein Profile in Women With Pregnancy Morbidity Associated With Antiphospholipid Syndrome.Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.Antibodies to serine proteases in the antiphospholipid syndrome.Tissue factor in antiphospholipid antibody-induced pregnancy loss: a pro-inflammatory molecule.Platelet activation and anti-phospholipid antibodies collaborate in the activation of the complement system on platelets in systemic lupus erythematosus.Maternal and fetal alternative complement pathway activation in early severe preeclampsiaDysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications.Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia.New therapeutic targets for the antiphospholipid syndrome.Pathophysiology of thrombosis and pregnancy morbidity in the antiphospholipid syndrome.Physiological and molecular determinants of embryo implantationTreatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management.Multiple steno-obstructive vascular lesions and femoral superficial artery dissection in a young Caucasian male with antiphospholipid syndrome.Gestation stage-dependent mechanisms of invariant natural killer T cell-mediated pregnancy lossComplement and systemic lupus erythematosus.A role for uric acid and the Nalp3 inflammasome in antiphospholipid antibody-induced IL-1β production by human first trimester trophoblast.New insights into mechanisms behind miscarriage.Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosisAutoimmunity and recurrent pregnancy losses.The alternative pathway of complement activation may be involved in the renal damage of human anti-glomerular basement membrane disease.Ovarian insufficiency and early pregnancy loss induced by activation of the innate immune systemA noninflammatory pathway for pregnancy loss: innate immune activation?Pathophysiology of the antiphospholipid antibody syndrome.Antiphospholipid syndrome: multiple mechanisms.Theodore E. Woodward Award: antiphospholipid syndrome revisited: a disorder initiated by inflammationExperimental Malaria in Pregnancy Induces Neurocognitive Injury in Uninfected Offspring via a C5a-C5a Receptor Dependent Pathway.Significant changes in the levels of secreted cytokines in brains of experimental antiphospholipid syndrome mice
P2860
Q24801311-B4A32FF4-E1CE-46D9-8044-BFFD22F2A898Q26741149-523739D4-54D5-481E-AC13-77B8DF978DB8Q26999710-1BF9CE1F-9477-4D61-A377-873B5130701BQ30409861-79AA52BB-0053-469A-8DEA-2255DB8FE5BDQ30497721-A5D73698-8041-48AC-BBE4-B4CDB80A33C5Q33300255-BE0295E1-C39D-4ADF-8786-F3F9CDE7BE7DQ33340467-8DECAFEB-D2E4-432D-BF29-47A895FB1C99Q33363684-3DD4D2F2-C9F5-4348-AB97-673E448505A9Q33365607-B0566915-2D37-4EED-BC3C-F16A88193473Q33382097-EE3D11FD-9033-4234-93D7-B46CE820801FQ33418663-C6637EE3-E67C-4D0B-99FE-E740058D6AB2Q33435712-5731D586-66B8-418F-94F3-8D18EBBF5DBEQ33591058-9E7C1C2D-29AD-4BAF-8A14-DB9AF1F5EE89Q33604935-9B33823B-9BFF-4BE8-9270-7529CA2FC35EQ33630007-42B501EC-6645-495F-BB0C-90BA5AC54C0CQ33670367-C9B329DC-2CE8-4BEF-BD3E-A8046303A4DAQ33741075-AE2F6512-E499-4ABF-86B4-AF38121B1DF1Q33748970-4C8AAB17-D560-4DF7-BD6C-F22FB6C873EAQ33795404-3065E918-4807-4E78-B4A6-B9BCA7E4D248Q33976312-CC541C71-8C17-4261-89C6-8AD9FB74D707Q34040357-0B7CC5D1-ADAE-47C0-9257-734074EE947AQ34140319-47DF3E1B-D335-4B1C-A362-D5093CF067E9Q34287356-A2E6A785-EECA-4EC9-A971-D03CE3AE4FD3Q34320970-4680ADAF-86CE-4B3A-B2A5-FBB384645D64Q34476952-6F54B02B-9742-49BD-9675-C07AD90FD669Q34534532-0000CFF3-A51E-4C71-95C7-F06520A7E64CQ34574847-E7CC3D12-9774-40E8-B9EB-659D6CA7C077Q34731255-06C58BE1-4C11-441B-96A2-1C67EA22DC6BQ34769721-F00CB5BF-8B86-4031-8B1D-C28D32171D24Q34784972-1F0EBF96-447B-4672-82D6-7C0E25C71ECEQ34963070-E3824B60-23B5-4AE3-AB2D-65FF6CC7A302Q35008643-5D9DD7B7-5BD1-43F8-93F4-8CFF5E89E262Q35127927-41D48934-809D-4883-9A23-030C983F093CQ35233081-712CC00C-3213-4B65-9885-C32B948006CFQ35233232-680BEEE8-E078-4816-9BC8-25646712C1B9Q35309024-C8F06D56-AADA-41ED-872C-DE5BD339819CQ35775322-4729136C-F2F9-48B1-A21F-A18B68A4C03EQ35778578-83C03B63-FDB4-4EC7-BA56-C308CAEC0A3BQ35786658-18BA60F6-CB99-4B86-818B-CEA64EE6D42DQ35791670-E6737639-1345-4B3C-8C92-19C5F03356B0
P2860
Complement C3 activation is required for antiphospholipid antibody-induced fetal loss.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Complement C3 activation is required for antiphospholipid antibody-induced fetal loss.
@ast
Complement C3 activation is required for antiphospholipid antibody-induced fetal loss.
@en
type
label
Complement C3 activation is required for antiphospholipid antibody-induced fetal loss.
@ast
Complement C3 activation is required for antiphospholipid antibody-induced fetal loss.
@en
prefLabel
Complement C3 activation is required for antiphospholipid antibody-induced fetal loss.
@ast
Complement C3 activation is required for antiphospholipid antibody-induced fetal loss.
@en
P2093
P2860
P356
P1476
Complement C3 activation is required for antiphospholipid antibody-induced fetal loss.
@en
P2093
Christopher G Vialpando
Dailing Mao
Hector Molina
Jane E Salmon
Liu E Xiaowei
Ricardo Espinola
Silvia S Pierangeli
V Michael Holers
P2860
P304
P356
10.1084/JEM.200116116
P407
P577
2002-01-01T00:00:00Z